Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Thoracic 6Gastrointestinal 3CNS 3Tumor-Agnostic 2Plasma cell 2Other solid neoplasm 2Other hematologic neoplasm 2Dermatologic 2Breast 2Sarcoma 1Lymphoid 1

Conditions

Glioma 3Glioblastoma 3Nervous System Neoplasms 2Nervous System Diseases 2Neoplasms 2Central Nervous System Neoplasms 2Central Nervous System Diseases 2Brain Neoplasms 2Brain Diseases 2Astrocytoma 2

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 80Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Adjuvants, Immunologic × CNS × Clear all
NCT01290692 2023-07-03

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

TVAX Biomedical

Phase 2 Completed
14 enrolled 11 charts
CNS

Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma, Neoplasms, Nervous System Diseases, Nervous System Neoplasms, Central Nervous System Neoplasms

NCT01081223 2023-06-01

Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma

TVAX Biomedical

Phase 1/2 Completed
12 enrolled 11 charts
CNS

Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma, Neoplasms, Nervous System Diseases, Nervous System Neoplasms, Central Nervous System Neoplasms

NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

NYU Langone Health

Phase 2 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡